| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Amir H Rezvani, Ehsan Kholdebarin, Elizabeth Dawson, Edward D Levi. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. The international journal of neuropsychopharmacology. vol 11. issue 1. 2008-04-15. PMID:17295931. |
given that the great majority of people with schizophrenia smoke, the potential beneficial effects of clozapine on attentional function may be largely blocked by self-administered nicotine. |
2008-04-15 |
2023-08-12 |
rat |
| Amir H Rezvani, Ehsan Kholdebarin, Elizabeth Dawson, Edward D Levi. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. The international journal of neuropsychopharmacology. vol 11. issue 1. 2008-04-15. PMID:17295931. |
however, in schizophrenia the efficacy of nicotinic treatments may be limited by co-treatment with antipsychotic drugs like clozapine. |
2008-04-15 |
2023-08-12 |
rat |
| Amir H Rezvani, Ehsan Kholdebarin, Elizabeth Dawson, Edward D Levi. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. The international journal of neuropsychopharmacology. vol 11. issue 1. 2008-04-15. PMID:17295931. |
it will be important to determine which of the complex effects of clozapine and nicotine are key in reversing attentional impairment and how they block each other's effects for the development of therapy to combat the attentional impairment of schizophrenia. |
2008-04-15 |
2023-08-12 |
rat |
| Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M Kester, Courtney De Thomas, Vivian Kafantaris, Christoph U Correll, John M Kan. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological psychiatry. vol 63. issue 5. 2008-04-14. PMID:17651705. |
clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. |
2008-04-14 |
2023-08-12 |
Not clear |
| Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M Kester, Courtney De Thomas, Vivian Kafantaris, Christoph U Correll, John M Kan. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological psychiatry. vol 63. issue 5. 2008-04-14. PMID:17651705. |
the present study evaluated the effectiveness and safety of clozapine versus "high-dose" olanzapine in treatment-refractory adolescents with schizophrenia. |
2008-04-14 |
2023-08-12 |
Not clear |
| Y-L Tang, P-X Mao, F Jiang, Q Chen, C-Y Wang, Z-J Cai, P B Mitchel. Clozapine in China. Pharmacopsychiatry. vol 41. issue 1. 2008-04-11. PMID:18203045. |
about 25-60% of all treated patients with schizophrenia receive clozapine; and clozapine is preferred by some as a first-line treatment for schizophrenia. |
2008-04-11 |
2023-08-12 |
Not clear |
| Y-L Tang, P-X Mao, F Jiang, Q Chen, C-Y Wang, Z-J Cai, P B Mitchel. Clozapine in China. Pharmacopsychiatry. vol 41. issue 1. 2008-04-11. PMID:18203045. |
clozapine is currently the most commonly used treatment for schizophrenia in china. |
2008-04-11 |
2023-08-12 |
Not clear |
| H-J Assion, H Reinbold, S Lemanski, M Basilowski, G Jucke. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. vol 41. issue 1. 2008-04-11. PMID:18203048. |
amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. |
2008-04-11 |
2023-08-12 |
Not clear |
| H-J Assion, H Reinbold, S Lemanski, M Basilowski, G Jucke. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. vol 41. issue 1. 2008-04-11. PMID:18203048. |
only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia. |
2008-04-11 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, William V Bobo, Ajanta Roy, Karu Jayathilake, Yuejin Chen, Aygun Ertugrul, A Elif Anil Yağcioğlu, Joyce G Smal. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of clinical psychiatry. vol 69. issue 2. 2008-04-04. PMID:18232726. |
a randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. |
2008-04-04 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, William V Bobo, Ajanta Roy, Karu Jayathilake, Yuejin Chen, Aygun Ertugrul, A Elif Anil Yağcioğlu, Joyce G Smal. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of clinical psychiatry. vol 69. issue 2. 2008-04-04. PMID:18232726. |
clozapine, despite its side-effect burden, has been considered to be the drug of choice for patients with schizophrenia whose psychotic symptoms fail to respond adequately to other anti-psychotic drugs. |
2008-04-04 |
2023-08-12 |
Not clear |
| Alan I Green, Douglas L Noordsy, Mary F Brunette, Christopher O'Keef. Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of substance abuse treatment. vol 34. issue 1. 2008-04-03. PMID:17574793. |
a neurobiological formulation is discussed, suggesting that the use of substances in patients with schizophrenia may be based on a dysfunction within the dopamine-mediated brain reward circuitry and that clozapine, in particular, may potentially ameliorate this dysfunction and lessen the desire for substance use. |
2008-04-03 |
2023-08-12 |
Not clear |
| Brian Parsons, Miriam Kenned. A review of recorded information given to patients starting to take clozapine and the development of guidelines on disclosure, a key component of informed consent. Journal of medical ethics. vol 33. issue 10. 2008-04-03. PMID:17906051. |
clozapine is a very effective drug with both significant benefits and significant risks in treatment-resistant schizophrenia. |
2008-04-03 |
2023-08-12 |
human |
| b' Aygun Ertugrul, Berna Ulu\\xc4\\x9. The effect of clozapine on neuroimaging findings in schizophrenia. Psychiatria Danubina. vol 19. issue 4. 2008-03-19. PMID:18000491.' |
the effect of clozapine on neuroimaging findings in schizophrenia. |
2008-03-19 |
2023-08-12 |
Not clear |
| b' Aygun Ertugrul, Berna Ulu\\xc4\\x9. The effect of clozapine on neuroimaging findings in schizophrenia. Psychiatria Danubina. vol 19. issue 4. 2008-03-19. PMID:18000491.' |
in particular, clozapine appears to act more selectively than typical antipsychotics on the prefrontal region, an area of special relevance in higher cognitive functions and schizophrenia. |
2008-03-19 |
2023-08-12 |
Not clear |
| b' Aygun Ertugrul, Berna Ulu\\xc4\\x9. The effect of clozapine on neuroimaging findings in schizophrenia. Psychiatria Danubina. vol 19. issue 4. 2008-03-19. PMID:18000491.' |
the study of anatomic and functional brain variables associated with clozapine response in schizophrenia may help to identify patients who are most likely to benefit from clozapine treatment. |
2008-03-19 |
2023-08-12 |
Not clear |
| Roberto Delle Chiaie, Massimo Salviati, Samantha Fiorentini, Massimo Biond. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Experimental and clinical psychopharmacology. vol 15. issue 6. 2008-03-17. PMID:18179309. |
this 8-week open label trial aimed to discover whether the addition of 30 mg mirtazapine could potentiate the effects on cognition of an ongoing stabilized clozapine therapy in 15 persons who met the criteria for chronic schizophrenia in the diagnostic and statistical manual of mental disorders (4th ed., text rev. |
2008-03-17 |
2023-08-12 |
Not clear |
| Roberto Delle Chiaie, Massimo Salviati, Samantha Fiorentini, Massimo Biond. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Experimental and clinical psychopharmacology. vol 15. issue 6. 2008-03-17. PMID:18179309. |
these findings suggest a potential role for mirtazapine as a useful strategy to augment the efficacy of clozapine in the treatment of cognitive dysfunctions in chronic schizophrenia. |
2008-03-17 |
2023-08-12 |
Not clear |
| P K Chandrasekara. Agranulocytosis monitoring with Clozapine patients: to follow guidelines or to attempt therapeutic controversies? Singapore medical journal. vol 49. issue 2. 2008-03-17. PMID:18301833. |
clozapine is an atypical antipsychotic with superior efficacy in the treatment of refractory schizophrenia. |
2008-03-17 |
2023-08-12 |
Not clear |
| Y Chertkow, O Weinreb, M B H Youdim, H Silve. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. Journal of neural transmission (Vienna, Austria : 1996). vol 114. issue 11. 2008-03-11. PMID:17576515. |
treating primary 'negative symptoms' of schizophrenia with a combination of a typical antipsychotic and a selective serotonin reuptake inhibitor, is more effective than with antipsychotic alone and is similar to the effect of the atypical antipsychotic, clozapine. |
2008-03-11 |
2023-08-12 |
rat |